老年人认知障碍筛查:美国预防服务工作组更新证据报告与系统综述
该系统综述纳入287项研究、超过28万名老年人,评估认知筛查工具的准确性及干预措施的获益与危害。一项RCT(n=4005)发现筛查对12个月健康相关生活质量无显著影响;MMSE检出痴呆的合并敏感度和特异度均为0.89;药物与心理教育干预获益较小且临床重要性不确定。
要点
- MMSE( cutoff ≤23或≤24)检出痴呆的合并敏感度0.89、特异度0.89。
- 仅1项RCT(n=4005)直接评估筛查效果,12个月生活质量无显著差异。
- 药物与照护者心理教育干预获益较小,临床重要性不确定。
核心结论
- 认知筛查工具能充分检出认知障碍,但无实证证据表明筛查改善患者或照护者结局或造成危害。
- 针对早期检出认知障碍患者或照护者的干预是否提供临床重要获益仍不明确。
研究设计与样本
- 系统综述纳入287项研究,超过28万名老年人,检索MEDLINE、PubMed、PsycINFO和Cochrane Central至2019年1月,文献监测至2019年11月22日。
- 纳入公平至良好质量的英文研究,涉及认知筛查工具及针对MCI、轻中度痴呆患者或照护者的药物与非药物治疗。
- 采用独立批判性评价与数据提取,随机效应荟萃分析与定性综合。
主要发现
- 1项RCT(n=4005)评估筛查对患者结局的直接效应,12个月健康相关生活质量效应量0.009(95%CI -0.063至0.080),无显著差异。
- 抗阿尔茨海默病药物(多奈哌齐、加兰他敏、利斯的明和美金刚)在3个月至3年内使ADAS-Cog 11评分改善1至2.5分。
- 照护者心理教育干预在3至12个月内对照护者负担有较小获益(标准化均数差-0.24,95%CI -0.36至-0.13)。
关键数值与推荐
- 筛查对12个月健康相关生活质量效应量0.009(95%CI -0.063至0.080),无显著差异(1项RCT,n=4005)。
- 抗阿尔茨海默病药物使ADAS-Cog 11评分改善1至2.5分(3个月至3年)。
- 照护者心理教育干预对照护者负担的标准化均数差-0.24(95%CI -0.36至-0.13)(3至12个月)。
临床怎么用
- 认知筛查工具可有效检出认知障碍,但筛查本身对患者或照护者结局的获益缺乏实证支持。
- 对已知MCI或轻中度痴呆患者,药物与照护者心理教育干预的获益较小且临床重要性不确定。
- 临床决策需权衡筛查检出与后续干预证据的局限性。
局限性
- 仅1项RCT直接评估筛查对患者结局的效应。
- 所有治疗试验均未与筛查项目关联,参与者为已知认知障碍者。
- 干预获益较小且临床重要性不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early identification of cognitive impairment may improve patient and caregiver health outcomes. OBJECTIVE: To systematically review the test accuracy of cognitive screening instruments and benefits and harms of interventions to treat cognitive impairment in older adults (≥65 years) to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, PsycINFO, and Cochrane Central Register of Controlled Trials through January 2019, with literature surveillance through November 22, 2019. STUDY SELECTION: Fair- to good-quality English-language studies of cognitive impairment screening instruments, and pharmacologic and nonpharmacologic treatments aimed at persons with mild cognitive impairment (MCI), mild to moderate dementia, or their caregivers. DATA EXTRACTION AND SYNTHESIS: Independent critical appraisal and data abstraction; random-effects meta-analyses and qualitative synthesis. MAIN OUTCOMES AND MEASURES: Sensitivity, specificity; patient, caregiver, and clinician decision-making; patient function, quality of life, and neuropsychiatric symptoms; caregiver burden and well-being. RESULTS: The review included 287 studies with more than 280 000 older adults. One randomized clinical trial (RCT) (n = 4005) examined the direct effect of screening for cognitive impairment on patient outcomes, including potential harms, finding no significant differences in health-related quality of life at 12 months (effect size, 0.009 [95% CI, -0.063 to 0.080]). Fifty-nine studies (n = 38 531) addressed the accuracy of 49 screening instruments to detect cognitive impairment. The Mini-Mental State Examination was the most-studied instrument, with a pooled sensitivity of 0.89 (95% CI, 0.85 to 0.92) and specificity of 0.89 (95% CI, 0.85 to 0.93) to detect dementia using a cutoff of 23 or less or 24 or less (15 studies, n = 12 796). Two hundred twenty-four RCTs and 3 observational studies including more than 240 000 patients or caregivers addressed the treatment of MCI or mild to moderate dementia. None of the treatment trials were linked with a screening program; in all cases, participants were persons with known cognitive impairment. Medications approved to treat Alzheimer disease (donepezil, galantamine, rivastigmine, and memantine) improved scores on the ADAS-Cog 11 by 1 to 2.5 points over 3 months to 3 years. Psychoeducation interventions for caregivers resulted in a small benefit for caregiver burden (standardized mean difference, -0.24 [95% CI, -0.36 to -0.13) over 3 to 12 months. Intervention benefits were small and of uncertain clinical importance. CONCLUSIONS AND RELEVANCE: Screening instruments can adequately detect cognitive impairment. There is no empirical evidence, however, that screening for cognitive impairment improves patient or caregiver outcomes or causes harm. It remains unclear whether interventions for patients or caregivers provide clinically important benefits for older adults with earlier detected cognitive impairment or their caregivers.
引用
- Patnode CD, Perdue LA, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020. PMID: 32096857. doi:10.1001/jama.2019.22258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。